Sales Reflected in Women's Health Insurance Products Starting July
Hanwha General Insurance announced on the 24th that its developed "Breast Cancer Prognosis Prediction Test Fee Rider" has obtained an exclusive usage right from the General Insurance Association for six months. This rider is a product planned in collaboration with Cha Hospital.
Hanwha General Insurance plans to incorporate this rider into a women's health insurance product to be launched in July. The main content is to provide coverage for the test fee, which uses the genes of breast cancer patients to predict personalized treatment and the likelihood of recurrence, for the first time and only once.
Hanwha General Insurance's Breast Cancer Prognosis Prediction Test Fee Rider received the highest score in terms of "usefulness," as it can prevent infertility, hair loss, depression, and other side effects that may occur from chemotherapy when a cancer patient is diagnosed through testing as not requiring chemotherapy. Additionally, it was highly evaluated for "originality" for pioneering coverage areas not included in indemnity health insurance, and for "progressiveness" in improving the quality of life by enabling cancer patients to receive accurate treatment tailored to their situation through genetic testing. The exclusive usage right for this rider applies for six months from the approval date.
After obtaining exclusive usage rights this year for breast cancer (receptor type) diagnosis fees and fertility preservation services encouraging childbirth, Hanwha General Insurance has acquired two exclusive usage rights solely in the third insurance sector.
A Hanwha General Insurance official stated, "The product was planned based on the idea that simply omitting chemotherapy after breast cancer surgery could improve the quality of life for female patients," adding, "As a company leading women's health management, we will strive to provide products that meet customer demands, minimize the costs and side effects of excessive chemotherapy, and enhance customer value."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
